<DOC>
	<DOCNO>NCT01663415</DOCNO>
	<brief_summary>The purpose study investigate radiographic progression-free survival ( PFS ) enzalutamide chemotherapy-naïve patient progressive metastatic castration-resistant prostate cancer symptomatic disease .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Enzalutamide Chemotherapy-Naïve , Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Progressive prostate cancer androgen deprivation therapy Castrate testosterone level Maintenance surgical medical castration duration study Radiographically visible metastatic disease Symptomatic prostate cancer Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy &gt; =6 month Brain metastasis leptomeningeal disease Prior cytotoxic chemotherapy prostate cancer Prior use ketoconazole abiraterone acetate investigational agent block androgen synthesis target androgen receptor History seizure condition may predispose seizure History loss consciousness transient ischemic attack within 12 month Clinically significant cardiovascular disease</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>enzalutamide</keyword>
</DOC>